Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
1997 | 1 |
2018 | 2 |
2019 | 1 |
2020 | 1 |
2023 | 1 |
2024 | 1 |
Search Results
5 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Atherosclerosis in subjects newly diagnosed with human immunodeficiency virus infection.
Biosci Rep. 2018 Jul 18;38(4):BSR20180597. doi: 10.1042/BSR20180597. Print 2018 Aug 31.
Biosci Rep. 2018.
PMID: 29961673
Free PMC article.
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials.
Orkin C, Molina JM, Cahn P, Lombaard J, Supparatpinyo K, Kumar S, Campbell H, Wan H, Teal V, Jin Xu Z, Asante-Appiah E, Sklar P, Teppler H, Lahoulou R; DRIVE-FORWARD and DRIVE-AHEAD collaborators.
Orkin C, et al.
Lancet HIV. 2024 Feb;11(2):e75-e85. doi: 10.1016/S2352-3018(23)00258-8. Epub 2023 Dec 20.
Lancet HIV. 2024.
PMID: 38141637
Clinical Trial.
Item in Clipboard
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Xu X, Rodgers A, Lupinacci L, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C; DRIVE-FORWARD Study Group.
Molina JM, et al.
Lancet HIV. 2018 May;5(5):e211-e220. doi: 10.1016/S2352-3018(18)30021-3. Epub 2018 Mar 25.
Lancet HIV. 2018.
PMID: 29592840
Clinical Trial.
Item in Clipboard
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.
Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Rodgers A, Lupinacci L, Kumar S, Sklar P, Hanna GJ, Hwang C, Martin EA; DRIVE-FORWARD trial group.
Molina JM, et al.
Lancet HIV. 2020 Jan;7(1):e16-e26. doi: 10.1016/S2352-3018(19)30336-4. Epub 2019 Nov 15.
Lancet HIV. 2020.
PMID: 31740348
Clinical Trial.
Item in Clipboard
[The estimation of the real hazards of chemical substances based on an analysis of the concentration (dose)-body status relationship].
Avaliani SL, Irodova EV, Pechennikova EV, Shimonova TE.
Avaliani SL, et al. Among authors: shimonova te.
Gig Sanit. 1997 Mar-Apr;(2):58-60.
Gig Sanit. 1997.
PMID: 9190346
Russian.
No abstract available.
Item in Clipboard
Cite
Cite